John Helou is a seasoned biopharmaceuticals and biotech industry executive with over 37 years of experience. He was a member of the Board of Directors of Starpax Biopharma from May 2022 until October 2024. Prior to retirement in 2020 he was President of Pfizer Canada for eight years, and Chair of the Board of Directors for Pfizer Canada and the Canadian Hospira Healthcare Corporation (following the acquisition) until retirement.

He has Led a biotech commercial Startup, and managed multiple integrations, divestitures and reorganizations that have always focused on increased shareholder value, operational fluidity, and employee engagement.

Throughout his tenure, John was known for his strategic vision in healthcare and leadership development. He has been a strong advocate for the life sciences sector and health care delivery with government and policy makers to establish operating environments that are globally competitive in Canada.

John was also Chair and later Vice Chair to the Board of Directors of Innovative Medicines Canada (IMC), member of the Board of Directors of BIOTECanada, a member of the Business Council of Canada, as well as Chair and Board member of the Advanced Coronary Treatment (ACT) Foundation.  He was inducted into the Marketing Hall of Fame in 2014.

He holds a Degree in Chemical Engineering from the University of Toronto.